BioSpace News Archive

Radiaction Medical, LTD announced that it has appointed industry veteran Christopher Barys to serve as its US President and Chief Commercial Officer.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced today that the company will be presenting 16 posters and exhibiting at booth 223 at the Society for Immunotherapy of Cancer (SITC) annual conference, taking place from November 1-5, 2023 in San Diego, CA.

LumaCyte is proud to announce the launch of their newly redesigned flagship Radiance® instrument to meet growing demand for Laser Force Cytology™ precision analytics in space-constrained biomanufacturing facilities.

BioArctic AB and partner Eisai are proud to announce that TIME has selected lecanemab as one of the Best Inventions of 2023 in the medical care category.

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today the presentation of posters and oral talks at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place October 22-25, 2023, in Barcelona, Spain.

Elpiscience Biopharmaceuticals, Inc. today announced it will have three poster presentations at the SITC 2023 Annual Meeting taking place November 3-5, 2023, in San Diego.

Aurion Biotech today announced that it has dosed the first subject in its Phase 1 / 2 U.S. clinical trial (ABA-1, CLARA) of AURN001.

Microbot Medical Inc., developer of the innovative LIBERTY® Robotic Surgical System, announces it has received confirmation for the commencement of the process to support its future CE Mark approval, and to ultimately allow the Company to market the LIBERTY® Robotic Surgical System in Europe as well as other regions who accept the CE Mark.

Neuronetics, Inc. today announced that it plans to release third quarter 2023 financial and operating results prior to market open on Tuesday, November 7th, 2023.

Quoin Pharmaceuticals Ltd. announces additional positive clinical data from its ongoing open-label study evaluating the safety and efficacy of QRX003 as a potential treatment for Netherton Syndrome (NS).